Checkpoint Therapeutics, Inc.
(NASDAQ CM: CKPT)
Rigrodsky Law, P.A. is investigating Checkpoint Therapeutics, Inc. (“Checkpoint”) regarding possible breaches of fiduciary duties and other violations of law related to Checkpoint’s agreement to be acquired by Sun Pharmaceutical Industries Limited. Under the terms of the agreement, Checkpoint shareholders will receive $4.10 per share in cash and a contingent value right for up to $0.70 per share on achievement of a milestone.